Justine Perino1, Nathan Mottal2, Yohann Bohbot3, Vincent Servant4, Aude Berroneau4, Pierre Poustis5, Pierre Fenaux6, Kamel Laribi7, Aude Charbonnier8, Emilien Bilion8, Claire Calmettes2, Bernard Bégaud9, Arnaud Pigneux2, Noël Milpied2, Ghada Miremont-Salamé1,9, Hélène Théophile1, Sophie Dimicoli-Salazar2. 1. CHU de Bordeaux, Pôle de Santé Publique, Service de pharmacologie médicale, Centre Régional de pharmacovigilance de Bordeaux, Bordeaux, France. 2. CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire Bordeaux, France. 3. CHU d'Amiens, Pôle Cœur-Thorax-Vaisseaux, Département de Cardiologie, Amiens Cedex, France. 4. Pharmacie à Usage Intérieur, CHU de Bordeaux, Pessac, France. 5. Service des soins intensifs cardiologiques Haut-Lévêque (intensive care unit), Pessac, France. 6. Service d'Hematologie Seniors, Hôpital Saint Louis, Ass Pub Hôp Paris and Paris 7 Université Paris, France. 7. Service d'Hematologie, Centre Hospitalier du Mans, Le Mans, France. 8. Service d'Hematologie, Institut Paoli Calmettes, Marseille, France. 9. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Centre, team Pharmacoepidemiology, Bordeaux, France.
Abstract
AIMS: Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF) and AZA exposure. METHODS: Cases of CF in patients treated with AZA were retrospectively collected and described from several centres of the Groupe Francophone des Myélodysplasies. A description analysis and a disproportionality analysis using Vigibase, the WHO Global Individual Case Safety Reports (ICSRs) database, were conducted on ICSRs by the Standardized MedDRA Queries (SMQ broad) cardiac failure and by preferred terms cardiac failure and cardiac failure acute. The reported odds ratio (ROR) and its 95% 2-sided confidence interval was computed by comparing the proportion of CF reports with the suspected drug (AZA) and the proportion of reports of the same adverse drug reaction with all other suspected drugs in the database during the same period. RESULTS: In the 4 case reports, all patients presented a cardiovascular history. In 1 patient, CF recurred after AZA re-challenge. The pharmacovigilance analysis in Vigibase retrieved 307 ICSRs of CF (SMQ) with AZA. Significant disproportionality signals associated with AZA were identified by using the SMQ cardiac failure (ROR 1.3) and the preferred terms cardiac failure (ROR 5.1) and cardiac failure acute (ROR 23.2). CONCLUSION: This study points to the potential role of AZA in the occurrence of CF. Cardiac evaluation before AZA initiation and regular monitoring of cardiac function during AZA treatment should be performed in patients with a history of cardiovascular disease.
AIMS: Azacitidine (AZA), a pyrimidine analogue, is validated for high-risk myelodysplastic syndrome or low-blast acute myeloid leukaemia in unfit patients for more intensive treatment. This study assessed the putative link between cardiac failure (CF) and AZA exposure. METHODS: Cases of CF in patients treated with AZA were retrospectively collected and described from several centres of the Groupe Francophone des Myélodysplasies. A description analysis and a disproportionality analysis using Vigibase, the WHO Global Individual Case Safety Reports (ICSRs) database, were conducted on ICSRs by the Standardized MedDRA Queries (SMQ broad) cardiac failure and by preferred terms cardiac failure and cardiac failure acute. The reported odds ratio (ROR) and its 95% 2-sided confidence interval was computed by comparing the proportion of CF reports with the suspected drug (AZA) and the proportion of reports of the same adverse drug reaction with all other suspected drugs in the database during the same period. RESULTS: In the 4 case reports, all patients presented a cardiovascular history. In 1 patient, CF recurred after AZA re-challenge. The pharmacovigilance analysis in Vigibase retrieved 307 ICSRs of CF (SMQ) with AZA. Significant disproportionality signals associated with AZA were identified by using the SMQ cardiac failure (ROR 1.3) and the preferred terms cardiac failure (ROR 5.1) and cardiac failure acute (ROR 23.2). CONCLUSION: This study points to the potential role of AZA in the occurrence of CF. Cardiac evaluation before AZA initiation and regular monitoring of cardiac function during AZA treatment should be performed in patients with a history of cardiovascular disease.
Authors: Mikkael A Sekeres; Alan F List; David Cuthbertson; Ronald Paquette; Rebecca Ganetzky; Rebecca Ganetsky; Deborah Latham; Katarina Paulic; Manuel Afable; Hussain I Saba; Thomas P Loughran; Jaroslaw P Maciejewski Journal: J Clin Oncol Date: 2010-03-30 Impact factor: 44.544
Authors: Steven D Gore; Pierre Fenaux; Valeria Santini; John M Bennett; Lewis R Silverman; John F Seymour; Eva Hellström-Lindberg; Arlene S Swern; Charles L Beach; Alan F List Journal: Haematologica Date: 2013-04-12 Impact factor: 9.941
Authors: Mikkael A Sekeres; Ramon V Tiu; Rami Komrokji; Jeffrey Lancet; Anjali S Advani; Manuel Afable; Ricki Englehaupt; Joyce Juersivich; David Cuthbertson; Jennifer Paleveda; Ali Tabarroki; Valeria Visconte; Hideki Makishima; Andres Jerez; Ronald Paquette; Alan F List; Jaroslaw P Maciejewski Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: Utz Krug; Anja Koschmieder; Daniela Schwammbach; Joachim Gerss; Nicola Tidow; Björn Steffen; Gesine Bug; Christian H Brandts; Markus Schaich; Christoph Röllig; Christian Thiede; Richard Noppeney; Matthias Stelljes; Thomas Büchner; Steffen Koschmieder; Ulrich Dührsen; Hubert Serve; Gerhard Ehninger; Wolfgang E Berdel; Carsten Müller-Tidow Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240
Authors: Dongsheng Hong; Jian Ni; Wenya Shan; Lu Li; Xi Hu; Hongyu Yang; Qingwei Zhao; Xingguo Zhang Journal: Zhejiang Da Xue Xue Bao Yi Xue Ban Date: 2020-05-25